Abstract
TRK inhibitors are used to treat adult and pediatric patients with solid tumors based on the presence of a neurotrophic tyrosine receptor kinase (NTRK) gene fusion. CHC2014, a highly selective pan-TRK inhibitor, shows anti-tumor activity against tumors harboring wild-type or solvent front mutated NTRK fusions in non-clinical studies. This is the first-in-human dose-escalation study of oral pan-TRK inhibitor, CHC2014, in subjects with advanced solid tumors.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
